SG11202101674QA - Methods and compositions for treating subjects having rheumatoid arthritis - Google Patents
Methods and compositions for treating subjects having rheumatoid arthritisInfo
- Publication number
- SG11202101674QA SG11202101674QA SG11202101674QA SG11202101674QA SG11202101674QA SG 11202101674Q A SG11202101674Q A SG 11202101674QA SG 11202101674Q A SG11202101674Q A SG 11202101674QA SG 11202101674Q A SG11202101674Q A SG 11202101674QA SG 11202101674Q A SG11202101674Q A SG 11202101674QA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- rheumatoid arthritis
- treating subjects
- subjects
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5412—IL-6
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862724212P | 2018-08-29 | 2018-08-29 | |
| US201862747301P | 2018-10-18 | 2018-10-18 | |
| US201962798697P | 2019-01-30 | 2019-01-30 | |
| US201962824399P | 2019-03-27 | 2019-03-27 | |
| US201962856431P | 2019-06-03 | 2019-06-03 | |
| US201962858443P | 2019-06-07 | 2019-06-07 | |
| EP19192387 | 2019-08-19 | ||
| PCT/US2019/048460 WO2020047029A1 (en) | 2018-08-29 | 2019-08-28 | Methods and compositions for treating subjects having rheumatoid arthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202101674QA true SG11202101674QA (en) | 2021-03-30 |
Family
ID=67851236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202101674QA SG11202101674QA (en) | 2018-08-29 | 2019-08-28 | Methods and compositions for treating subjects having rheumatoid arthritis |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11319375B2 (en) |
| EP (1) | EP3843852A1 (en) |
| JP (1) | JP2022502350A (en) |
| KR (1) | KR20210049871A (en) |
| CN (1) | CN112955222A (en) |
| AU (1) | AU2019329958A1 (en) |
| BR (1) | BR112021003206A2 (en) |
| CA (1) | CA3110891A1 (en) |
| CL (1) | CL2021000483A1 (en) |
| IL (1) | IL280824A (en) |
| MA (1) | MA53481A (en) |
| MX (1) | MX2021002422A (en) |
| PH (1) | PH12021550416A1 (en) |
| SG (1) | SG11202101674QA (en) |
| TW (1) | TW202026035A (en) |
| WO (1) | WO2020047029A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3180369A1 (en) * | 2020-05-26 | 2021-12-02 | Inka Albrecht | Compositions comprising an antibody against interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using same |
| KR20230031015A (en) * | 2021-08-26 | 2023-03-07 | 주식회사 이뮨메드 | Antibody pharmaceuticals for preventing or treating autoimmune disease |
| CN117138126B (en) * | 2023-08-30 | 2024-04-09 | 江苏恰瑞生物科技有限公司 | Filtering material for directionally removing inflammatory factor IL-6 and filtering column |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5171840A (en) | 1988-01-22 | 1992-12-15 | Tadamitsu Kishimoto | Receptor protein for human B cell stimulatory factor-2 |
| US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
| ES2156859T5 (en) | 1991-03-18 | 2008-03-16 | New York University | SPECIFIC MONOCLONAL AND CHEMICAL ANTIBODIES FOR THE HUMAN TUMOR NECROSIS FACTOR. |
| JP3370324B2 (en) | 1991-04-25 | 2003-01-27 | 中外製薬株式会社 | Reshaped human antibodies to human interleukin-6 receptor |
| US5215534A (en) | 1991-12-02 | 1993-06-01 | Lawrence De Harde | Safety syringe system |
| AU670125B2 (en) | 1992-09-15 | 1996-07-04 | Immunex Corporation | Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists |
| PT783893E (en) | 1994-10-07 | 2012-05-24 | Chugai Pharmaceutical Co Ltd | Inhibition of abnormal growth of synovial cells using il-6 antagonist as active ingredient |
| US6046223A (en) | 1996-02-26 | 2000-04-04 | Advanced Research & Technology Institute | Treatment of macular edema |
| AU7824900A (en) | 1999-10-07 | 2001-04-23 | Eli Lilly And Company | Compounds and methods for inhibiting mrp1 |
| US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| CA2385745C (en) | 2001-06-08 | 2015-02-17 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| CA2519870A1 (en) | 2003-04-09 | 2004-10-28 | Genentech, Inc. | Use of rituximab intravenous compositions to treat rheumatoid arthritis |
| CN1989439B (en) | 2004-05-06 | 2010-12-29 | 美国政府健康及人类服务部 | Methods and compositions for the treatment of uveitis |
| CA2575838A1 (en) | 2004-07-26 | 2006-03-30 | Biogen Idec Ma Inc. | Anti-cd154 antibodies |
| DK1963368T6 (en) | 2005-12-13 | 2020-06-29 | Lilly Co Eli | Anti-IL-17 ANTIBODIES |
| US20080131374A1 (en) | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
| PT2374818E (en) | 2006-06-02 | 2013-02-13 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| US8080248B2 (en) | 2006-06-02 | 2011-12-20 | Regeneron Pharmaceuticals, Inc. | Method of treating rheumatoid arthritis with an IL-6R antibody |
| FR2920033B1 (en) | 2007-08-13 | 2014-08-22 | Snecma | TURBOMACHINE WITH DIFFUSER |
| TWI440469B (en) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| JP4885308B2 (en) | 2009-03-19 | 2012-02-29 | 中外製薬株式会社 | Formulations containing improved antibody molecules |
| JO3030B1 (en) | 2009-06-26 | 2016-09-05 | Galapagos Nv | Novel Compound Useful for the Treatment of Degenerative and Inflammatory Diseases |
| WO2011006273A1 (en) * | 2009-07-15 | 2011-01-20 | Eva Kovacs-Benke | Combination of a human interleukin-6 antagonist and a human interleukin-6 receptor antagonist in therapy of tumour diseases |
| JO3417B1 (en) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies |
| SG2014014724A (en) | 2010-05-07 | 2014-07-30 | Xoma Technology Ltd | METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS |
| US9427531B2 (en) | 2010-06-28 | 2016-08-30 | Sanofi-Aventis Deutschland Gmbh | Auto-injector |
| TWI568888B (en) | 2011-09-15 | 2017-02-01 | 第諾拉工業公司 | Gas-diffusion electrode |
| TWI589299B (en) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | Compositions for the treatment of rheumatoid arthritis and methods of using same |
| US9943594B2 (en) | 2011-10-11 | 2018-04-17 | Sanofi Biotechnology | Methods for the treatment of rheumatoid arthritis |
| US9248242B2 (en) | 2012-04-20 | 2016-02-02 | Safety Syringes, Inc. | Anti-needle stick safety device for injection device |
| EP3042202A1 (en) * | 2013-09-03 | 2016-07-13 | Graham, L. Douglas | Treatment methods for rheumatoid arthritis |
| KR20230155586A (en) | 2013-11-22 | 2023-11-10 | 사노피 바이오테크놀로지 | Compositions for the treatment of rheumatoid arthritis and methods of using same |
| WO2015116852A1 (en) * | 2014-01-29 | 2015-08-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating rheumatoid arthritis by administering an il-6r antibody |
| WO2016044343A1 (en) | 2014-09-16 | 2016-03-24 | Sanofi Biotechnology | Compositions for improving the health related quality of life of rheumatoid arthritis patients |
| CA3003874A1 (en) | 2015-11-03 | 2017-05-11 | Sanofi Biotechnology | Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same |
| SG10202012182YA (en) * | 2016-03-07 | 2021-01-28 | Sanofi Biotechnology | Compositions and methods for treating rheumatoid arthritis |
-
2019
- 2019-08-28 SG SG11202101674QA patent/SG11202101674QA/en unknown
- 2019-08-28 MA MA053481A patent/MA53481A/en unknown
- 2019-08-28 CA CA3110891A patent/CA3110891A1/en active Pending
- 2019-08-28 EP EP19763150.0A patent/EP3843852A1/en active Pending
- 2019-08-28 TW TW108130759A patent/TW202026035A/en unknown
- 2019-08-28 WO PCT/US2019/048460 patent/WO2020047029A1/en unknown
- 2019-08-28 BR BR112021003206-1A patent/BR112021003206A2/en unknown
- 2019-08-28 MX MX2021002422A patent/MX2021002422A/en unknown
- 2019-08-28 AU AU2019329958A patent/AU2019329958A1/en active Pending
- 2019-08-28 CN CN201980065880.1A patent/CN112955222A/en active Pending
- 2019-08-28 JP JP2021510860A patent/JP2022502350A/en active Pending
- 2019-08-28 US US16/553,338 patent/US11319375B2/en active Active
- 2019-08-28 KR KR1020217008732A patent/KR20210049871A/en unknown
-
2021
- 2021-02-11 IL IL280824A patent/IL280824A/en unknown
- 2021-02-25 CL CL2021000483A patent/CL2021000483A1/en unknown
- 2021-02-26 PH PH12021550416A patent/PH12021550416A1/en unknown
-
2022
- 2022-03-23 US US17/701,748 patent/US20230059376A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022502350A (en) | 2022-01-11 |
| AU2019329958A1 (en) | 2021-03-18 |
| CL2021000483A1 (en) | 2021-07-19 |
| PH12021550416A1 (en) | 2021-09-27 |
| CN112955222A (en) | 2021-06-11 |
| IL280824A (en) | 2021-04-29 |
| MA53481A (en) | 2021-07-07 |
| BR112021003206A2 (en) | 2021-05-25 |
| KR20210049871A (en) | 2021-05-06 |
| CA3110891A1 (en) | 2020-03-05 |
| WO2020047029A1 (en) | 2020-03-05 |
| TW202026035A (en) | 2020-07-16 |
| MX2021002422A (en) | 2021-07-15 |
| US11319375B2 (en) | 2022-05-03 |
| US20230059376A1 (en) | 2023-02-23 |
| EP3843852A1 (en) | 2021-07-07 |
| US20200102395A1 (en) | 2020-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280134A (en) | Anti-cd112r compositions and methods | |
| IL275506A (en) | Compositions and methods for treating cns disorders | |
| GB2578539B (en) | Compositions and methods for preventing or treating muscle conditions | |
| IL275562A (en) | Compositions and methods for treating cns disorders | |
| IL280824A (en) | Methods and compositions for treating subjects having rheumatoid arthritis | |
| IL261515A (en) | Compositions and methods for treating rheumatoid arthritis | |
| IL271256A (en) | Compositions and methods for treating tauopathies | |
| IL269637A (en) | Compositions and methods for treating synucleinopathies | |
| IL275539A (en) | Compositions and methods for inhibiting aldh2 expression | |
| SG11202103033WA (en) | Compositions and methods for the treatment of presbyopia | |
| SG11202012055PA (en) | Methods and compositions for preventing or treating calciphylaxis | |
| IL285886A (en) | Compositions and methods for treating laminopathies | |
| ZA202101362B (en) | Compositions and methods for treating the eye | |
| IL262830A (en) | Compositions and methods for treating spinal muscular atrophy | |
| SG11202104448WA (en) | Compositions and methods | |
| ZA202101342B (en) | Compositions and methods for treating the eye | |
| IL269743A (en) | Methods and compositions for treating retina-associated disease using ccr3-inhibitors | |
| GB201816911D0 (en) | Apparatus and methods | |
| IL269550A (en) | Compositions and methods for treating synucleinopathies | |
| EP3628006A4 (en) | Compositions and methods for treating rheumatoid arthritis | |
| GB201817444D0 (en) | Methods and compositions | |
| ZA202101360B (en) | Compositions and methods for treating the eye | |
| ZA202101361B (en) | Compositions and methods for treating the eye | |
| IL277463A (en) | Compositions and methods for treating pruritus | |
| IL288573A (en) | Compositions and methods for treating pain in subjects with rheumatoid arthritis |